Page 7 - Processa Pharmaceuticals News Today

HANOVER, MD, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing...

/PRNewswire/ -- DelveInsights Pancreatic Cancer Market Insights report includes a comprehensive understanding of current treatment practices, pancreatic...

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) was the recipient of a significant increase in short interest during the month of May. As of May 31st, there was short interest totalling 123,500 shares, an increase of 31.9% from the May 15th total of 93,600 shares. Currently, 1.1% of the company’s shares are sold short. Based […]

Brokerages predict that Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) will announce earnings of ($0.26) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Processa Pharmaceuticals’ earnings. Processa Pharmaceuticals posted earnings per share of ($0.20) in the same quarter last year, which would indicate a negative year-over-year growth rate of […]

BeyondSpring (NASDAQ:BYSI – Get Rating) and Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations. Valuation & Earnings This table compares BeyondSpring and Processa Pharmaceuticals’ […]

Equities analysts predict that Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) will report earnings of ($0.24) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Processa Pharmaceuticals’ earnings. Processa Pharmaceuticals reported earnings per share of ($0.14) during the same quarter last year, which suggests a negative year […]

05.05.2022 - HANOVER, MD, May 05, 2022 (GLOBE NEWSWIRE) - Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need ...

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totalling 79,600 shares, a decrease of 21.2% from the March 15th total of 101,000 shares. Currently, 0.7% of the shares of the company are sold short. Based on […]

Zacks Investment Research upgraded shares of Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) from a sell rating to a hold rating in a report released on Wednesday, Zacks.com reports. According to Zacks, “Processa Pharmaceuticals, Inc. is focused on the development of drug products which intended to improve the survival and/or quality of life for patients who […]

Wall Street brokerages expect Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) to post earnings per share of ($0.18) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Processa Pharmaceuticals’ earnings. Processa Pharmaceuticals reported earnings of ($0.90) per share in the same quarter last year, which indicates a positive year-over-year […]